Thursday 28th February 2019
8:30am - 4:30pm
Pan Pacific Melbourne
This workshop is designed to support clinical staff working in drug & alcohol settings, or with people who inject drugs, to treat patients living with hepatitis C.
This session has been developed in collaboration with drug and alcohol clinicians, hepatology specialists, GPs, nurses and representatives from drug user community organisations.
This Education Program is designed to give participants the confidence, knowledge and decision-making skills to be able to prescribe new Direct Acting Antiviral (DAA) therapies for the treatment of HCV infection, either independently or in collaboration with a specialist as appropriate.
This course is being offered as a pre-conference Workshop to the 2019 International Medicine in Addiction Conference (IMiA Conference). This course is offered in collaboration with the Kirby Institute, UNSW Australia.Learning Outcomes:
- describe the risk factors for HCV infection enabling effective screening and prevention education
- demonstrate competence conducting and interpreting tests to diagnose HCV
- recognise risk factors, clinical signs, symptoms and complications of liver disease
- demonstrate understanding of DAA therapy for the treatment of HCV and competence in selecting appropriate therapy
- describe recommended on-treatment monitoring and post-treatment follow up protocols.